MedTrace Logo

Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)

NCT00044902 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2007-12-28

No results posted yet for this study

Summary

Epratuzumab is currently being studied in combination with rituximab, for the treatment of patients with low-grade NHL who failed previous chemotherapy and have never received rituximab or who received rituximab as a single agent or in combination with chemotherapy as their last treatment and who demonstrated a partial response or complete response for at least 12 months.

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

DRUG

epratuzumab

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00044902 on ClinicalTrials.gov